HYQVIA

Takeda Pharmaceuticals America, Inc.🇺🇸 United States

FDA Page

Effective Date: Jun 18, 2026
Approval ID: 7ca2c26f-4be2-48cd-be5b-486e350654ba
Products: 5 registered
Version: 23

Regulatory Information

Labeling Type

PLASMA DERIVATIVE

Status

Approved

Full Title

These highlights do not include all the information needed to use HYQVIA safely and effectively. See full prescribing information for HYQVIA. HYQVIA [Immune Globulin Infusion (Human), 10% with Recombinant Human Hyaluronidase] Solution, for subcutaneous administration Initial U.S. Approval: 2014

Quick Stats

Total Products5

Labelers2

Label Sections54

Regulatory Agency

🇺🇸

U.S. Food and Drug Administration

United States

Data Sources & Disclaimer: Approval information is sourced from official FDA databases. This content is for informational purposes only and does not constitute medical or regulatory advice. Always refer to official FDA websites for the most current information.